SI1439829T1 - Zdravilo, ki vsebuje 3-(3-dimetilamino-1-etil-2-metil-propil)fenol, z zapoznelim sproscanjem aktivne snovi - Google Patents

Zdravilo, ki vsebuje 3-(3-dimetilamino-1-etil-2-metil-propil)fenol, z zapoznelim sproscanjem aktivne snovi

Info

Publication number
SI1439829T1
SI1439829T1 SI200230224T SI200230224T SI1439829T1 SI 1439829 T1 SI1439829 T1 SI 1439829T1 SI 200230224 T SI200230224 T SI 200230224T SI 200230224 T SI200230224 T SI 200230224T SI 1439829 T1 SI1439829 T1 SI 1439829T1
Authority
SI
Slovenia
Prior art keywords
dimethylamino
phenol
propyl
ethyl
methyl
Prior art date
Application number
SI200230224T
Other languages
English (en)
Slovenian (sl)
Inventor
Johannes Bartholomaeus
Iris Ziegler
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26010444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1439829(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10152469A external-priority patent/DE10152469A1/de
Priority claimed from DE2002148309 external-priority patent/DE10248309A1/de
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of SI1439829T1 publication Critical patent/SI1439829T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SI200230224T 2001-10-24 2002-10-22 Zdravilo, ki vsebuje 3-(3-dimetilamino-1-etil-2-metil-propil)fenol, z zapoznelim sproscanjem aktivne snovi SI1439829T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10152469A DE10152469A1 (de) 2001-10-24 2001-10-24 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
DE2002148309 DE10248309A1 (de) 2002-10-16 2002-10-16 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung
PCT/EP2002/011809 WO2003035053A1 (de) 2001-10-24 2002-10-22 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung
EP02781278A EP1439829B1 (de) 2001-10-24 2002-10-22 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
SI1439829T1 true SI1439829T1 (sl) 2006-02-28

Family

ID=26010444

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230224T SI1439829T1 (sl) 2001-10-24 2002-10-22 Zdravilo, ki vsebuje 3-(3-dimetilamino-1-etil-2-metil-propil)fenol, z zapoznelim sproscanjem aktivne snovi

Country Status (28)

Country Link
US (7) US20050058706A1 (OSRAM)
EP (1) EP1439829B1 (OSRAM)
JP (2) JP4758064B2 (OSRAM)
KR (1) KR100958045B1 (OSRAM)
CN (1) CN100402021C (OSRAM)
AR (1) AR036943A1 (OSRAM)
AT (1) ATE303802T1 (OSRAM)
AU (1) AU2002349001C1 (OSRAM)
BR (1) BRPI0213653B8 (OSRAM)
CA (1) CA2464578C (OSRAM)
CO (1) CO5570662A2 (OSRAM)
CY (1) CY2012022I2 (OSRAM)
DE (1) DE50204198D1 (OSRAM)
DK (1) DK1439829T3 (OSRAM)
EC (1) ECSP045102A (OSRAM)
ES (1) ES2248622T3 (OSRAM)
HU (1) HU230161B1 (OSRAM)
IL (2) IL161587A0 (OSRAM)
MX (1) MXPA04003742A (OSRAM)
MY (1) MY127797A (OSRAM)
NO (2) NO331896B1 (OSRAM)
NZ (1) NZ532999A (OSRAM)
PE (1) PE20030527A1 (OSRAM)
PL (1) PL216535B1 (OSRAM)
PT (1) PT1439829E (OSRAM)
SI (1) SI1439829T1 (OSRAM)
WO (2) WO2003035053A1 (OSRAM)
ZA (1) ZA200403928B (OSRAM)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP3241550B1 (de) 2002-11-22 2020-07-22 Grünenthal GmbH (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol zur behandlung von entzündungsschmerz
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
PL1658054T3 (pl) * 2003-08-06 2007-11-30 Gruenenthal Gmbh Postać aplikacyjna zabezpieczona przed nadużyciem
ATE368639T1 (de) * 2004-06-28 2007-08-15 Gruenenthal Gmbh Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CA2572352A1 (en) * 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
MX2008013828A (es) * 2006-04-28 2008-11-10 Gruenenthal Gmbh Combinacion farmaceutica que comprende 3-(3-dimetilanimo-1-etil-2- metil-propil)-fenol y un nsaid.
WO2007128413A1 (en) * 2006-04-28 2007-11-15 Grünenthal GmbH Pharmaceutical combination comprising 3- ( 3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
CN101091725A (zh) * 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
EP2596784B1 (en) * 2007-11-23 2016-12-21 Grünenthal GmbH Tapentadol compositions
ES2764451T3 (es) * 2007-12-07 2020-06-03 Gruenenthal Gmbh Modificaciones cristalinas del (1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol
AU2009207796B2 (en) * 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
HRP20161307T1 (hr) 2008-05-09 2016-12-02 Grünenthal GmbH Postupak za pripravu praškaste formulacije međuproizvoda i konačni kruti oblik doziranja uz korištenje koraka zgrušavanja raspršivanjem
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
SI2352494T1 (sl) 2008-10-30 2019-12-31 Gruenenthal Gmbh Nove in potentne dozirne oblike tapentadola
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
PE20120631A1 (es) 2009-07-22 2012-06-06 Gruenenthal Chemie Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion
CN102821757B (zh) * 2010-02-03 2016-01-20 格吕伦塔尔有限公司 通过挤出机制备粉末状药物组合物
WO2011124953A2 (en) * 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
EP2566461A2 (de) * 2010-05-05 2013-03-13 Ratiopharm GmbH Festes tapentadol in nicht-kristalliner form
ES2560676T3 (es) * 2010-06-15 2016-02-22 Grünenthal GmbH Combinación farmacéutica para el tratamiento del dolor
SI2588093T1 (sl) 2010-06-30 2016-10-28 Gruenenthal Gmbh Tapentadol za uporabo pri zdravljenju sindroma razdražljivega črevesja
ES3035088T3 (en) 2010-07-23 2025-08-28 Gruenenthal Gmbh Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
PL2611426T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
AR082862A1 (es) 2010-09-02 2013-01-16 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico
JP6027549B2 (ja) 2011-03-04 2016-11-16 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールを含む半固形の水性医薬組成物
JP6046057B2 (ja) 2011-03-04 2016-12-14 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 経口投与用タペンタドールの水性医薬製剤
KR101903351B1 (ko) 2011-03-04 2018-10-04 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여
EP2694049B1 (en) 2011-04-05 2018-10-31 Grünenthal GmbH Tapentadol for preventing chronification of pain
JP6040219B2 (ja) 2011-04-05 2016-12-07 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 三叉神経因性痛に伴う疼痛の治療用タペンタドール
DK3272343T3 (da) 2011-04-29 2020-04-27 Gruenenthal Gmbh Tapentadol til hindring og behandling af depression og angst
BR112014000969A2 (pt) * 2011-07-29 2017-04-18 Gruenenthal Gmbh administração intratecal ou epidural de 3-[(1s,2s)-3-(dimetilamino)- 1-etil-2-metilpropil]fenol
HRP20171458T1 (hr) 2011-07-29 2017-11-17 Grünenthal GmbH Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
KR20140053159A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
EP2606879A1 (en) 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EA032465B1 (ru) 2013-07-12 2019-05-31 Грюненталь Гмбх Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
EP2942054A1 (en) * 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
MX2017012312A (es) 2015-03-27 2018-01-18 Gruenenthal Gmbh Formulacion estable para administracion parenteral de tapentadol.
HK1246173A1 (zh) 2015-04-24 2018-09-07 Grünenthal GmbH 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
WO2018055070A1 (en) 2016-09-23 2018-03-29 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
WO2018219897A1 (en) * 2017-05-29 2018-12-06 Grünenthal GmbH Multiparticulate oral dosage form providing prolonged release of tapentadol
AU2020100441B4 (en) * 2020-03-02 2020-06-18 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
DE202021003994U1 (de) 2020-03-02 2022-04-12 Grünenthal GmbH Dosierungsform mit verlängerter Freisetzung von Tapentadol-Phosphorsäuresalz
EP3875080B1 (en) 2020-03-02 2025-12-31 Grünenthal GmbH EXTENDED-RELEASE DOSAGE FORM OF PHOSPHORIC ACID SALT OF TAPENTADOL
AU2020100442B4 (en) * 2020-03-02 2020-06-18 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
RS65074B1 (sr) * 2020-03-02 2024-02-29 Gruenenthal Gmbh Dozni oblik sa produženim oslobađanjem soli tapentadola sa fosfornom kiselinom
ES3010208T3 (en) * 2020-03-16 2025-04-01 Gruenenthal Gmbh Scored tablet comprising tapentadol
DE202020104285U1 (de) 2020-07-24 2020-12-18 Grünenthal GmbH Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure
WO2022101247A1 (de) 2020-11-10 2022-05-19 Grünenthal GmbH Darreichungsformen mit verlängerter freisetzung eines salzes von tapentadol mit l-(+)-weinsäure
DE202020005470U1 (de) 2020-11-10 2022-01-25 Grünenthal GmbH Darreichungsformen mit verlängerter Freisetzung eines Salzes von Tapentadol mit L-(+)-Weinsäure
PT3995135T (pt) * 2020-11-10 2022-09-08 Gruenenthal Gmbh Forma de dosagem que proporciona libertação prolongada de um sal de tapentadol com ácido l-(+)-tartárico

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
DE2117239A1 (de) 1971-04-08 1972-11-16 König, Wilhelm, 4712 Werne Verfahren zum Erstellen von Wänden aus Schalungssteinen
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5641632A (en) 1983-01-10 1997-06-24 Gen-Probe Incorporated Method for preparing rRNA for hybridization with a probe
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
GB8519310D0 (en) 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
DK0661045T3 (da) * 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4329794C2 (de) 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
SG44669A1 (en) 1993-11-17 1997-12-19 Traditional Cn Med Res Lab Inc Compositions for curing affected abnormal tissues method for the preparation thereof and usage thereof
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
CN1125572A (zh) * 1994-12-28 1996-07-03 顺德市广容制药厂 一种罗通定痛释片的制作方法
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
DE19525137C2 (de) 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
DE19609847A1 (de) 1996-03-13 1997-09-18 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
IL123505A (en) * 1996-07-08 2004-12-15 Penwest Pharmaceuticals Compan Sustained release matrix for high-dose insoluble drugs
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
WO1998055107A1 (en) * 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
DE19901683B4 (de) 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
RU2230556C2 (ru) * 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
DE10248309A1 (de) 2002-10-16 2004-04-29 Grünenthal GmbH 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung

Also Published As

Publication number Publication date
BR0213653A (pt) 2004-10-26
NO2012007I1 (no) 2012-05-21
EP1439829A1 (de) 2004-07-28
NZ532999A (en) 2007-06-29
PT1439829E (pt) 2005-11-30
DK1439829T3 (da) 2005-10-10
PL216535B1 (pl) 2014-04-30
CY2012022I1 (el) 2015-08-05
US20170087103A1 (en) 2017-03-30
JP2010280697A (ja) 2010-12-16
DE50204198D1 (de) 2005-10-13
BRPI0213653B8 (pt) 2021-05-25
JP4758064B2 (ja) 2011-08-24
PE20030527A1 (es) 2003-07-26
US20180221308A1 (en) 2018-08-09
NO2012007I2 (no) 2013-01-02
CN1607947A (zh) 2005-04-20
WO2003035053A1 (de) 2003-05-01
ECSP045102A (es) 2004-06-28
WO2003035054A1 (de) 2003-05-01
US20130237608A1 (en) 2013-09-12
AU2002349001C1 (en) 2022-04-14
US20160151309A1 (en) 2016-06-02
MXPA04003742A (es) 2004-07-23
US20200038344A1 (en) 2020-02-06
HK1068539A1 (en) 2005-04-29
KR20040047964A (ko) 2004-06-05
US20120034304A1 (en) 2012-02-09
AU2002349001B2 (en) 2003-05-06
CN100402021C (zh) 2008-07-16
ZA200403928B (en) 2005-07-27
PL369756A1 (en) 2005-05-02
US11007156B2 (en) 2021-05-18
IL161587A (en) 2009-12-24
CO5570662A2 (es) 2005-10-31
BRPI0213653B1 (pt) 2018-04-03
NO331896B1 (no) 2012-04-30
CY2012022I2 (el) 2015-08-05
HU230161B1 (en) 2015-09-28
NO20041924L (no) 2004-05-11
MY127797A (en) 2006-12-29
KR100958045B1 (ko) 2010-05-17
EP1439829B1 (de) 2005-09-07
IL161587A0 (en) 2004-09-27
ATE303802T1 (de) 2005-09-15
ES2248622T3 (es) 2006-03-16
AR036943A1 (es) 2004-10-13
CA2464578C (en) 2011-10-11
HUP0402104A2 (hu) 2005-03-29
JP2005506367A (ja) 2005-03-03
CA2464578A1 (en) 2003-05-01
US20050058706A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
PL369756A1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
AU2002349001A1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
AU9208601A (en) Delayed release pharmaceutical formulations
HUP0302949A3 (en) Active ingredient combinations comprising insecticidal and acaricidal properties and use thereof
IL163866A0 (en) 8-Azaprostaglandin derivative compounds and drugs containing the compounds s active ingredient
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
HUP0302847A3 (en) Pharmaceutical formulation comprising bicalutamide
AU2001291781A1 (en) Active ingredient combinations comprising insecticidal and acaricidal properties
AU2002245629A1 (en) Stabilized therapeutic and imaging agents
EP1424994A4 (en) PREPARATION OF A SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION
HUP0303454A3 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
HUP0401911A3 (en) Pesticidal formulations and their use
HUP0303260A3 (en) Agrochemical formulations, preparation and use thereof
IL161902A0 (en) Pharmaceutical formulation comprising bicalutamide
AU2002340573A8 (en) Powdery active ingredient formulations
GB0119848D0 (en) Delayed and sustained drug release
IL148546A0 (en) Active ingredient combinations having insecticidal and acaricidal properties
HUP0401644A3 (en) Aminobenzoephenones, pharmaceutical compositions containing them and use thereof
AU1556000A (en) Composition allowing predefined and controlled release of active ingredient, preparation thereof and use
IL160886A0 (en) Nicotine containing pharmaceutical formulations and use thereof
AU2002346860A1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
AU2002339169A1 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenyl sulphonyl)-2-hydroxy-2-methylpropiono- m toluidide, pvp, an anti-oestrogen and/or an aromatase inhibitor
AU2002250977A1 (en) Combination of active ingredients consisting of the racemate of tramadol and of (+)-o-desmethyltramadol
HUP0401229A3 (en) Crystal form of a phenylethanolamine hydrokloride, the preparation thereof and pharmaceutical compositions comprising the same
IL152751A0 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them